Carvana Insider Sold Shares Worth $13,723,323, According to a Recent SEC Filing-February 2024-www.financetom.com

Carvana Insider Sold Shares Worth $13,723,323, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Carvana Insider Sold Shares Worth $13,723,323, According to a Recent SEC Filing

Feb 19, 2025 1:10 AM

03:39 AM EST, 02/19/2025 (MT Newswires) -- Mark W. Jenkins, Chief Financial Officer, on February 14, 2025, sold 48,422 shares in Carvana ( CVNA ) for $13,723,323. Following the Form 4 filing with the SEC, Jenkins has control over a total of 219,962 Class A common shares of the company, with 219,962 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1690820/000169082025000068/xslF345X05/wk-form4_1739922759.xml

Previous page： Incyte's Potential Colorectal, Pancreatic Cancer Treatments Merit 'Continued Clinical Development' Next page： Johnson & Johnson Reports 45% Response Rate for Subcutaneous Amivantamab in Head and Neck Cancer Study

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Incyte's Potential Colorectal, Pancreatic Cancer Treatments Merit 'Continued Clinical Development'

Oct 20, 2025

05:53 AM EDT, 10/20/2025 (MT Newswires) -- Incyte ( INCY ) said Monday that data from clinical testing of the therapies INCA33890 for patients with microsatellite stable colorectal cancer and its INCB161734 for patients with specifically pancreatic ductal adenocarcinoma support continued clinical development and show favorable safety profiles. A phase 1 trial of INCA33890 Phase 1 trial of 260 patients...

Johnson & Johnson Reports 45% Response Rate for Subcutaneous Amivantamab in Head and Neck Cancer Study

Oct 20, 2025

05:31 AM EDT, 10/20/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Sunday that its subcutaneous formulation of amivantamab showed an overall response rate of 45% in a phase 1b/2 study involving patients with recurrent or metastatic head and neck squamous cell carcinoma unrelated to human papillomavirus, following disease progression after prior checkpoint inhibitor and platinum-based chemotherapy. In...

Form 8.3 - Alpha Group International PLC

Oct 20, 2025

LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...

Neighbourhood Holdings Acquires Fisgard Asset Management, Creating One of Canada’s Largest Alternative Mortgage Lenders

Oct 20, 2025

VANCOUVER, BC / ACCESS Newswire ( ACCS ) / October 20, 2025 / Neighbourhood Holdings Ltd. (Neighbourhood) is excited to announce its landmark acquisition of Fisgard Asset Management Corporation (Fisgard), creating one of Canada's largest mortgage investment entities and marking a major milestone in Canada's alternative mortgage industry. This transaction marks a significant consolidation and brings together two of the...